Phase II trial of weekly docetaxel and gemcitabine as first-line therapy for patients with advanced non-small cell lung cancer

By Kalmadi Sujith   McNeill Giles   Davis Mellar   Peereboom David   Adelstein David   Mekhail Tarek  

Medical Oncology, Vol. 23, Iss. 4, 2006-12 ,pp. : 507-513

Humana Press, Inc

Access to resources Recommend Favorite

Phase II Trial of Docetaxel in Asian Patients with Inoperable Stage III Non-Small Cell Lung Cancer

By Goh Boon C.   Lehnert Manfred   Lim Hong L.   Ng Alan W. K.   Chan Choong C.   Kong Hwai L.   Lee Soo C.   Wee Joseph   Chua E. T.   Wong John E. L.  

Acta Oncologica, Vol. 39, Iss. 2, 2000-08 ,pp. : 225-229

Informa Healthcare

Access to resources Recommend Favorite

Phase II study of irinotecan and amrubicin in patients with relapsed non-small cell lung cancer: Okayama Lung Cancer Study Group Trial 0402

By Nogami Naoyuki   Hotta Katsuyuki   Segawa Yoshihiko   Takigawa Nagio   Hosokawa Shinobu   Oze Isao   Fujii Masanori   Ichihara Eiki   Shibayama Takuo   Tada Atsuhiko   Hamada Noboru   Uno Masatoshi   Tamaoki Akihiko   Kuyama Shoichi   Ikeda Genyo   Osawa Masahiro   Takata Saburo   Tabata Masahiro   Tanimoto Mitsune   Kiura Katsuyuki  

Acta Oncologica, Vol. 51, Iss. 6, 2012-07 ,pp. : 768-773

Informa Healthcare

Access to resources Recommend Favorite

Phase II trial of capecitabine combined with docetaxel in previously treated patients with non-small cell lung cancer: A randomized controlled study

By                        

Oncology Letters, Vol. 3, Iss. 4, 2012-01 ,pp. : 761-766

Spandidos Publications

Access to resources Recommend Favorite

Activity and safety of erlotinib as second- and third-line treatment in elderly patients with advanced non-small cell lung cancer: a phase II trial

By Rossi David  

Targeted Oncology, Vol. 5, Iss. 4, 2010-12 ,pp. : 231-235

Springer Publishing Company

Access to resources Recommend Favorite